Outset Medical Q4 revenue falls

Outset Medical

11/02/2026 21:09

Overview

Medical technology firm's Q4 revenue fell 2% yr/yr

Gross margin for Q4 expanded nearly 600 basis points

Outlook

Outset Medical projects 2026 revenue between $125 mln and $130 mln

Company expects non-GAAP gross margin in low to mid-40% range for 2026

Outset Medical plans to launch next-gen Tablo platform in Q2 2026

Result Drivers

GROSS MARGIN EXPANSION - Gross margin improved by nearly 600 basis points in Q4 due to cost management and operational efficiencies

RECURRING REVENUE GROWTH - Recurring revenue from Tablo consumables and services grew 6% in 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$19.49 mln
Q4 Gross Margin
42.40%
Q4 Basic EPS
-$1.09
Q4 Gross Profit
$12.23 mln
Q4 Operating Expenses
$29.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Outset Medical Inc is $11.50, about 144.7% above its February 10 closing price of $4.70

Press Release: ID:nGNX9W75vK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)